FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 354:437-440 February 2, 2006 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The Food and Drug Administration (FDA) has been struggling for nearly two decades over the possible approval of a do-it-yourself home test for human immunodeficiency virus (HIV). Now, after years of politicking and lawsuits, it finally looks possible. Last November, after OraSure Technologies announced that it was seeking over-the-counter status for its rapid HIV-antibody test, the FDA convened a panel of experts to determine the requirements for approval of a home test. The OraQuick test, which is widely used in clinics, works like a home pregnancy test, except that it uses oral fluid instead of urine.

(Figure)

View larger version (40K):   The . . . [Full Text of this Article]

 

Source Information

Drs. Wright and Katz are residents in internal medicine at Brigham and Women's Hospital, Boston, and editorial fellows at the Journal.

This article has been cited by other articles:

• Gray, R. H, Makumbi, F., Serwadda, D., Lutalo, T., Nalugoda, F., Opendi, P., Kigozi, G., Reynolds, S. J, Sewankambo, N. K, Wawer, M. J (2007). Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study. BMJ 335: 188-188 [Abstract] [Full Text]